Japanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimer’s, does not improve the brain’s waste clearance system in the short term. This implies that nerve damage and impaired clearance occur early and are difficult to reverse. Their findings underscore that tackling amyloid alone may not be enough to restore brain function, urging a broader approach to treatment.
Source: https://www.sciencedaily.com/releases/2 ... 005944.htm
-
Translation